165 related articles for article (PubMed ID: 36302965)
21. Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasets.
Wakuda T; Benner S; Uemura Y; Nishimura T; Kojima M; Kuroda M; Matsumoto K; Kanai C; Inada N; Harada T; Kameno Y; Munesue T; Inoue J; Umemura K; Yamauchi A; Ogawa N; Kushima I; Suyama S; Saito T; Hamada J; Kano Y; Honda N; Kikuchi S; Seto M; Tomita H; Miyoshi N; Matsumoto M; Kawaguchi Y; Kanai K; Ikeda M; Nakamura I; Isomura S; Hirano Y; Onitsuka T; Ozaki N; Kosaka H; Okada T; Kuwabara H; Yamasue H
Brain Behav Immun; 2024 May; 118():398-407. PubMed ID: 38461957
[TBL] [Abstract][Full Text] [Related]
22. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.
Yamasue H; Okada T; Munesue T; Kuroda M; Fujioka T; Uno Y; Matsumoto K; Kuwabara H; Mori D; Okamoto Y; Yoshimura Y; Kawakubo Y; Arioka Y; Kojima M; Yuhi T; Owada K; Yassin W; Kushima I; Benner S; Ogawa N; Eriguchi Y; Kawano N; Uemura Y; Yamamoto M; Kano Y; Kasai K; Higashida H; Ozaki N; Kosaka H
Mol Psychiatry; 2020 Aug; 25(8):1849-1858. PubMed ID: 29955161
[TBL] [Abstract][Full Text] [Related]
23. Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism.
Owada K; Okada T; Munesue T; Kuroda M; Fujioka T; Uno Y; Matsumoto K; Kuwabara H; Mori D; Okamoto Y; Yoshimura Y; Kawakubo Y; Arioka Y; Kojima M; Yuhi T; Yassin W; Kushima I; Benner S; Ogawa N; Kawano N; Eriguchi Y; Uemura Y; Yamamoto M; Kano Y; Kasai K; Higashida H; Ozaki N; Kosaka H; Yamasue H
Brain; 2019 Jul; 142(7):2127-2136. PubMed ID: 31096266
[TBL] [Abstract][Full Text] [Related]
24. Chronic oxytocin administration stimulates the oxytocinergic system in children with autism.
Moerkerke M; Daniels N; Tibermont L; Tang T; Evenepoel M; Van der Donck S; Debbaut E; Prinsen J; Chubar V; Claes S; Vanaudenaerde B; Willems L; Steyaert J; Boets B; Alaerts K
Nat Commun; 2024 Jan; 15(1):58. PubMed ID: 38167302
[TBL] [Abstract][Full Text] [Related]
25. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).
Spanos M; Chandrasekhar T; Kim SJ; Hamer RM; King BH; McDougle CJ; Sanders KB; Gregory SG; Kolevzon A; Veenstra-VanderWeele J; Sikich L
Contemp Clin Trials; 2020 Nov; 98():106103. PubMed ID: 32777383
[TBL] [Abstract][Full Text] [Related]
26. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.
Cacciotti-Saija C; Langdon R; Ward PB; Hickie IB; Scott EM; Naismith SL; Moore L; Alvares GA; Redoblado Hodge MA; Guastella AJ
Schizophr Bull; 2015 Mar; 41(2):483-93. PubMed ID: 24962607
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.
Quintana DS; Westlye LT; Hope S; Nærland T; Elvsåshagen T; Dørum E; Rustan Ø; Valstad M; Rezvaya L; Lishaugen H; Stensønes E; Yaqub S; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
Transl Psychiatry; 2017 May; 7(5):e1136. PubMed ID: 28534875
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.
Cai Q; Feng L; Yap KZ
Psychiatry Clin Neurosci; 2018 Mar; 72(3):140-151. PubMed ID: 29232031
[TBL] [Abstract][Full Text] [Related]
29. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder.
Zimmerman AW; Singh K; Connors SL; Liu H; Panjwani AA; Lee LC; Diggins E; Foley A; Melnyk S; Singh IN; James SJ; Frye RE; Fahey JW
Mol Autism; 2021 May; 12(1):38. PubMed ID: 34034808
[TBL] [Abstract][Full Text] [Related]
30. Changes in endogenous oxytocin levels after intranasal oxytocin treatment in adult men with autism: An exploratory study with long-term follow-up.
Alaerts K; Steyaert J; Vanaudenaerde B; Wenderoth N; Bernaerts S
Eur Neuropsychopharmacol; 2021 Feb; 43():147-152. PubMed ID: 33309460
[TBL] [Abstract][Full Text] [Related]
31. Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial.
Kruppa JA; Gossen A; Oberwelland Weiß E; Kohls G; Großheinrich N; Cholemkery H; Freitag CM; Karges W; Wölfle E; Sinzig J; Fink GR; Herpertz-Dahlmann B; Konrad K; Schulte-Rüther M
Neuropsychopharmacology; 2019 Mar; 44(4):749-756. PubMed ID: 30390065
[TBL] [Abstract][Full Text] [Related]
32. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism.
Auyeung B; Lombardo MV; Heinrichs M; Chakrabarti B; Sule A; Deakin JB; Bethlehem RA; Dickens L; Mooney N; Sipple JA; Thiemann P; Baron-Cohen S
Transl Psychiatry; 2015 Feb; 5(2):e507. PubMed ID: 25668435
[TBL] [Abstract][Full Text] [Related]
33. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
Kuppens RJ; Donze SH; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
[TBL] [Abstract][Full Text] [Related]
34. Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial.
Kong XJ; Liu J; Liu K; Koh M; Sherman H; Liu S; Tian R; Sukijthamapan P; Wang J; Fong M; Xu L; Clairmont C; Jeong MS; Li A; Lopes M; Hagan V; Dutton T; Chan SP; Lee H; Kendall A; Kwong K; Song Y
Nutrients; 2021 May; 13(5):. PubMed ID: 34062986
[TBL] [Abstract][Full Text] [Related]
35. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism.
Parker KJ; Oztan O; Libove RA; Mohsin N; Karhson DS; Sumiyoshi RD; Summers JE; Hinman KE; Motonaga KS; Phillips JM; Carson DS; Fung LK; Garner JP; Hardan AY
Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043522
[TBL] [Abstract][Full Text] [Related]
36. Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis.
Huang Y; Huang X; Ebstein RP; Yu R
Neurosci Biobehav Rev; 2021 Mar; 122():18-27. PubMed ID: 33400920
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome.
Fastman J; Foss-Feig J; Frank Y; Halpern D; Harony-Nicolas H; Layton C; Sandin S; Siper P; Tang L; Trelles P; Zweifach J; Buxbaum JD; Kolevzon A
Mol Autism; 2021 Sep; 12(1):62. PubMed ID: 34593045
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.
Aman MG; Findling RL; Hardan AY; Hendren RL; Melmed RD; Kehinde-Nelson O; Hsu HA; Trugman JM; Palmer RH; Graham SM; Gage AT; Perhach JL; Katz E
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):403-412. PubMed ID: 26978327
[TBL] [Abstract][Full Text] [Related]
39. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
[TBL] [Abstract][Full Text] [Related]
40. Effects of single- and multiple-dose oxytocin treatment on amygdala low-frequency BOLD fluctuations and BOLD spectral dynamics in autism.
Alaerts K; Bernaerts S; Wenderoth N
Transl Psychiatry; 2022 Sep; 12(1):393. PubMed ID: 36127337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
